Findings from Department of Vascular Surgery Yields New Data on Thrombosis (A Comparison of Venaseal Versus Radiofrequency Ablation Outcomes Within a Managed Care Organization): Cardiovascular Diseases and Conditions – Thrombosis

2024 FEB 14 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Current study results on Cardiovascular Diseases and Conditions - Thrombosis have been published. According to news reporting originating from Pasadena, California, by NewsRx correspondents, research stated, “Chronic venous insufficiency is a common medical condition that afflicts over 30 million adults in the United States. Treatment and management have changed dramatically over the past 20 years with the introduction of various endovenous therapies, including radiofre-quency ablation (RFA) and cyanoacrylate closure using the Venaseal system.”

Our news editors obtained a quote from the research from the Department of Vascular Surgery, “In this study, we explore a direct comparison of outcomes between RFA and VenaSeal conducted by a single surgeon within a managed care organization. Between May 2020 and December 2021, there were 87 patients undergoing 97 total procedures who were treated with either VenaSeal (n = 55) or RFA (n = 42), conducted by a single surgeon within a managed care organization. Primary outcomes included successful greater saphenous vein (GSV) closure, postoperative deep vein thrombosis (DVT), emboliza-tion, saphenofemoral junction (SFJ) thrombosis, skin reaction (allergic or thrombophlebitis), or procedure-related emergency room (ER) and urgent care (UC) visits. Retrospective chart review was conducted to describe patient demographics, indications for treatment, treatment details (number of access sites and indication for treatment), as well as follow-up adjunctive vein pro-cedures (sclerotherapy and stab phlebectomy). All patients had postprocedural ultrasound (US) performed within 7 days by the oper-ating surgeon and mean overall patient follow-up from index procedure was 12 months; 2 pa-tients were lost to follow-up due to death. All operations utilized intraoperative US, and SFJ thrombosis was not observed in any patient postprocedure. The average age of VenaSeal and RFA groups was 59.05 and 59.51 years, respectively. The average number of access sites during the procedure for VenaSeal and RFA was 1.56 and 1.20, respectively. Of the 55 Vena-Seal treatments, 9.1% of patients reported postoperative skin reactions, and 9.1% of patients underwent subsequent stab phlebectomy (22 stabs on average). Of the 42 RFA treatments, 7.1% of RFA patients reported postoperative skin reactions, and 9.5% underwent subsequent stab phlebectomy (36 stabs on average). The percentage of patients who had postoperative UC or emergency department visits related to the procedure in the VenaSeal and RFA groups was 3.6% and 0%, respectively. Both VenaSeal and RFA demonstrated effective vein closure of the GSV at 12 -month follow-up, with VenaSeal demonstrating continued noninferiority to RFA.”

According to the news editors, the research concluded: “Based on our data, postoperative skin reactions do not appear to be significantly higher with VenaSeal treat-ment, as previously reported.”

This research has been peer-reviewed.

For more information on this research see: A Comparison of Venaseal Versus Radiofrequency Ablation Outcomes Within a Managed Care Organization. Annals of Vascular Surgery, 2024;99:75-81. Annals of Vascular Surgery can be contacted at: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA. (Elsevier - www.elsevier.com; Annals of Vascular Surgery - http://www.journals.elsevier.com/annals-of-vascular-surgery/)

The news editors report that additional information may be obtained by contacting Iden Andacheh, Kaiser Permanente Bernard J Tyson Sch Med, Dept. of Vascular Surgery, Pasadena, CA, United States. Additional authors for this research include Jeffrey Hsu, Truong Vo, Jason Behseresht and Majid Tayyarah.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.avsg.2023.09.088. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)